← Eichor
Condition: Myelodysplastic Syndromes Previously Treated Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myelodysplastic Syndromes Previously Treated

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT027278033'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Phase 1/Phase 2 · 1 location(s) · Lixte Biotechnology Holdings, Inc. · NCT03886662Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · 348 location(s) · National Cancer Institute (NCI) · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory
Phase 1 · 3 location(s) · Jennifer Saultz · NCT03874052Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosi
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01624805
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.